158 related articles for article (PubMed ID: 24924837)
1. Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
Kao YT; Hsu WC; Hu HT; Hsu SH; Lin CS; Chiu CC; Lu CY; Hour TC; Pu YS; Huang AM
Kaohsiung J Med Sci; 2014 Jul; 30(7):323-30. PubMed ID: 24924837
[TBL] [Abstract][Full Text] [Related]
2. UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity.
Huang AM; Kao YT; Toh S; Lin PY; Chou CH; Hu HT; Lu CY; Liou JY; Chao SY; Hour TC; Pu YS
Biochem Pharmacol; 2011 Jul; 82(1):35-42. PubMed ID: 21477582
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Zhao Y; Shen S; Guo J; Chen H; Greenblatt DY; Kleeff J; Liao Q; Chen G; Friess H; Leung PS
J Surg Res; 2006 Dec; 136(2):325-35. PubMed ID: 17054996
[TBL] [Abstract][Full Text] [Related]
4. Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells.
Koizumi K; Tanno S; Nakano Y; Habiro A; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Anticancer Res; 2005; 25(5):3347-53. PubMed ID: 16101149
[TBL] [Abstract][Full Text] [Related]
5. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
7. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Liu F; Gore AJ; Wilson JL; Korc M
PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
[TBL] [Abstract][Full Text] [Related]
9. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells.
Habiro A; Tanno S; Koizumi K; Izawa T; Nakano Y; Osanai M; Mizukami Y; Okumura T; Kohgo Y
Biochem Biophys Res Commun; 2004 Mar; 316(1):71-7. PubMed ID: 15003513
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Wattanawongdon W; Hahnvajanawong C; Namwat N; Kanchanawat S; Boonmars T; Jearanaikoon P; Leelayuwat C; Techasen A; Seubwai W
Int J Oncol; 2015 Jul; 47(1):398-410. PubMed ID: 25998688
[TBL] [Abstract][Full Text] [Related]
13. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877
[TBL] [Abstract][Full Text] [Related]
14. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
15. Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
Pattarawat P; Hong T; Wallace S; Hu Y; Donnell R; Wang TH; Tsai CL; Wang J; Wang HR
Br J Cancer; 2020 Jul; 123(2):226-239. PubMed ID: 32390005
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
17. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
18. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
19. Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Huang XL; Zhang H; Yang XY; Dong XY; Xie XY; Yin HB; Gou X; Lin Y; He WY
Anticancer Drugs; 2017 Jul; 28(6):596-602. PubMed ID: 28430744
[TBL] [Abstract][Full Text] [Related]
20. Subamolide A, a component isolated from Cinnamomum subavenium, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1.
Liu CH; Chen CY; Huang AM; Li JH
J Ethnopharmacol; 2011 Sep; 137(1):503-11. PubMed ID: 21708241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
